Compare CRDL & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | ACU |
|---|---|---|
| Founded | 2017 | 1867 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1M | 160.6M |
| IPO Year | 2017 | 1994 |
| Metric | CRDL | ACU |
|---|---|---|
| Price | $1.24 | $41.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 360.1K | 19.2K |
| Earning Date | 05-14-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 1.63 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $196,541,816.00 |
| Revenue This Year | N/A | $5.67 |
| Revenue Next Year | N/A | $5.25 |
| P/E Ratio | ★ N/A | $175.67 |
| Revenue Growth | N/A | ★ 1.05 |
| 52 Week Low | $0.88 | $35.50 |
| 52 Week High | $1.71 | $47.31 |
| Indicator | CRDL | ACU |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 50.97 |
| Support Level | $0.94 | $40.54 |
| Resistance Level | $1.38 | $43.18 |
| Average True Range (ATR) | 0.06 | 1.37 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 9.09 | 75.50 |
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.